The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and ...

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

NYSE:PFE Earnings and Revenue History November 11th 2025 How Do Unusual Items Influence Profit? To properly understand Pfizer ...

The bidding war between Pfizer ( PFE) and Novo Nordisk ( NVO) over obesity drug developer Metsera ( MTSR) finally ended over ...

VYM has gained 9.9% in 2025 and has generated a cumulative 3-year return of 44.38% and a 5-year return of 105.33%. It remains ...

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more ...

Pfizer not only beat expectations last quarter, but also boosted its guidance.

On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an ...

Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington.

Pfizer’s offer of up to $86.25 in cash for each share of obesity drugs developer Metsera share tops the up to $86.20 Novo ...

US stocks rose Monday as Nvidia led tech gains, Apple delayed the iPhone Air, Pfizer acquired Metsera, and Trump unveiled a ...

US stocks rose on Monday as investors reacted to progress toward ending the US government shutdown of 40 days. The S&P 500 ...